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Sphingosine-1-phosphate (S1P) helps mediate
lymphocyte egress from lymph nodes, yet many
mechanistic questions remain. Here, we show the
presence of B lymphocyte egress sites located in
the lymph node cortex close to lymph node follicles.
B cells exited lymph nodes by squeezing through
apparent portals in the lymphatic endothelium of
these sinusoids. Treatment with the S1P receptor
agonist FTY720 emptied the cortical sinusoids of
lymphocytes, blocked lymphatic endothelial pene-
tration, and displaced B lymphocytes into the T cell
zone. S1pr3/ B cells, which lack chemoattractant
responses to S1P, transited lymph nodes normally,
whereas Gnai2/ B cells, which have impaired
responses to chemokines and S1P, transited more
rapidly than did wild-type cells. This study identifies
a major site of B lymphocyte lymph node egress,
shows that FTY720 treatment blocks passage
through the cortical lymphatic endothelium, and
argues against a functional role for S1P chemotaxis
in B lymphocyte egress.
INTRODUCTION
The afferent lymph is low in lymphocytes, whereas the efferent
lymph is highly enriched (Hall and Morris, 1965; Young, 1999).
This discrepancy arises because peripheral blood lymphocytes
enter lymph nodes from the blood but exit via efferent
lymphatics, eventually returning to the blood (Gowans, 1957).
Researchers have done a great deal of work at the microanatom-
ical level to understand this lymphocyte recirculation. Early light-
microscopic study of ultra-thin sections of rodent lymph nodes
revealed an interesting sinus structure termed a ‘‘mud stream’’
that appeared connected downstream to the medullary sinus
and extended upstream into the outer cortex (Soderstrom and
Stenstrom, 1969). Colloidal carbon injection into afferent
lymphatics of the rat mesenteric lymph node revealed connec-
tions between the subcapsular, intermediate (cortical), and
medullary sinuses (Anderson and Anderson, 1975). The interme-
diate sinuses formed a lymphatic plexus that surrounded follicles434 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.and high endothelial venules (HEVs). Scanning electron micros-
copy of casts prepared by resin injection of rabbit mesenteric
lymph nodes also revealed tubular cortical sinuses that
branched and anastomosed to other such structures (Kurokawa
and Ogata, 1980). Later, labyrinth-like structures filled with
lymphocytes were described in rat mesenteric lymph nodes
(He, 1985). These labyrinths were found close to HEVs, under-
neath follicles, and they probably correspond to the cortical
sinus network described in the other studies. They were sug-
gested to be involved in exit of lymphocytes from lymph nodes
(He, 1985). Despite these early studies documenting cortical
lymphoid sinuses, most egress studies have focused on the
medullary sinus (Mandala et al., 2002).
Description of a pertussis toxin-sensitive G protein signaling
pathway needed for thymocyte emigration was the beginning of
our understanding of the molecular requirement for lymphocyte
egress from primary and secondary lymphoid organs (Chaffin
and Perlmutter, 1991). More recently, the immunosuppressive
drug FTY720, its analogs, and other related molecules have
shed additional light on the molecular mechanisms of lympho-
cyte egress (Cyster, 2005). Treatment of mice with FTY720
inhibits T cell emigration from the thymus and egress from lymph
nodes (Yagi et al., 2000; Mandala et al., 2002). In vivo FTY720 is
converted to an active phosphate moiety (FTY720-P) via the
activity of the sphingolipid kinases SPHK1 and SPHK2 (Billich
et al., 2003; Paugh et al., 2003). FTY720-P displays agonist
activity at all of the sphingosine-1-phosphate receptors
(S1PRs), with the exception of S1PR2 (Brinkmann et al., 2002).
The absence of S1PR1 expression on mouse hematopoietic cells
produced results reminiscent to those observed with FTY720
treatment, given that mature S1pr1/ T lymphocytes exited
poorly from secondary lymphoid tissues and the thymus (Allende
et al., 2004; Lo et al., 2005; Matloubian et al., 2004). These results
argued that S1PR1 is an essential part of the mechanism utilized
by lymphocytes for their egress from secondary lymphoid tissues
and the thymus. The FTY720 results were explained by showing
that FTY720-P can act as a functional antagonist, triggering
receptor internalization and degradation. This would make
lymphocytes unresponsive to the S1P present in the efferent
lymph that presumably attracts lymphocytes from the lymph
node parenchyma into the medullary sinus. However, others
have argued that the S1PR1-deficient lymphocytes are abnormal
and that S1P predominantly acts on receptors present on
lymphatic endothelial cells to control lymphocyte egress (Alfonso
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B Cell Egress from Lymph Nodeset al., 2006; Mandala et al., 2002). In this scenario, FTY720-P acts
as an agonist on lymphatic endothelial cells to trigger closure of
the lymphatic endothelial barrier (Rosen et al., 2003). Further
support for the second model has come from imaging the
behavior of T cells in the medullary sinus region of the lymph
node after treatment with S1PR1 agonists, later reversed with
S1PR1 antagonists (Sanna et al., 2006; Wei et al., 2005).
The ultrastructural studies of lymph nodes suggest that
lymphocytes not only exit by crossing the medullary sinuses,
Figure 1. LYVE-1-Positive Lymphatics Adjacent to the Lymph Node
Follicles Are Emptied by FTY720 Treatment
(A) Confocal images of untreated lymph node sections immunostained for
LYVE-1 and B220. The top left panel shows LYVE-1 staining alone, and the
top right panel shows B220 and LYVE-1 with a 100 mm thick section. The
bottom left panel shows a 53 zoomed image of the B220- and LYVE-1-stained
section (white square). The bottom right image shows a single optical section.
Arrows show B cells within the LYVE-1-positive lymphatic.
(B) 100 mm lymph node section immunostained for LYVE-1 and optically
sectioned by confocal microscopy.
(C) A section from the lymph node follicle and T cell zone interface immuno-
stained for B220, LYVE-1, and CD3. T cell zone lymphatics are indicated
with an arrowhead, and those adjacent to the lymph node follicle are indicated
with an arrow.
(D) Lymph node from FTY720-treated mice immunostained for B220 and
LYVE-1. Left and middle panels show B220 staining and B220 and LYVE-1
staining, respectively. The right panel is a 43 zoomed image of the interface
between the lymph node follicle and T cell zone (white square in previous
image) immunostained with B220 and LYVE-1. Empty lymphatic sinusoids in
the B cell zone (indicated by the left arrow) and T cell zone (indicated by the
right arrow) are indicated.but may also enter lymphatics in the cortical region around
follicles. The presence of an exit route adjacent to the lymph
node follicle makes sense given that it becomes unnecessary
for B cells to cross the T lymphocyte-rich cortical area to enter
into the medullary lymphatics. With this in mind, we examined
the location of lymphatics in relation to the lymph node follicle
and determined whether they support the exit of B lymphocytes
by using conventional immunohistochemistry. Because of their
relatively superficial location within the lymph node, intravital
two-photon laser scanning microscopy (TP-LSM) could be
used for observing B cell behavior near these efferent lymphatic
channels. By blocking the entrance of new cells, we could
examine those cells that have remained within the lymph node
follicle for a defined duration in the presence or absence of
S1P analogs. In addition, we have made use of B cells prepared
fromS1pr3/mice and fromGnai2/mice, which have defects
in S1P-mediated chemotaxis. Together, these studies have
shown that lymph node cortical lymphatics serve as a major
egress site for B cells, that S1PR1 does not trigger B cell chemo-
taxis, that S1P-mediated chemotaxis does not have an apparent
role in B lymphocyte egress, and that on the basis of the imaging
data, it is very likely that a major function of S1PR1 signaling is to
directly facilitate the movement of B cells across the lymphatic
endothelium and into the efferent lymph.
RESULTS
Lymphatics Adjacent to Lymph Node Follicles
Are Emptied of B Lymphocytes by FTY720 Treatment
We studied thick sections of lymph node with confocal micros-
copy after staining tissue for LYVE-1, a lymphatic endothelium-
specific receptor for hyaluronan (Banerji et al., 1999), and B220
(Figure 1A). In the outer cortex of lymph nodes, we observed
lymphatic channels in very close proximity to follicles. These
lymphatics were situated at the boundary of the follicle and the
T cell zone. We saw a few follicles whose complete apical
surface was covered by lymphatics. Optical sectioning showed
that these channels were filled with B lymphocytes. At some
places, these lymphatics were connected to the lymphatics in
the deep cortex and medullary sinuses. A partial three-dimen-
sional reconstruction of the LYVE-1-positive structures adjacent
to a lymph node follicle is shown (Figure 1B). Whereas
lymphatics around follicles were filled with B lymphocytes,
lymphatics in the deep cortex mainly contained T lymphocytes
and few B cells (Figure 1C).
The above results indicated that the lymphatics around the
lymph node follicle support the egress of B lymphocytes from
follicles. To further address this issue, we gavaged mice with
FTY720 to block the exit of lymphocytes into lymphatics.
Confocal imaging of lymph nodes from FTY720-treated mice
clearly showed that the lumens of the lymphatics around the
follicles were completely devoid of B lymphocytes (Figure 1D).
Because the exit was blocked by FTY720, numerous B lympho-
cytes were found in the adjacent T cell area. We did not see this
kind of encroachment in control lymph node sections.
Relocation of B Lymphocytes in the Lymph Node Follicle
The average residence time for B lymphocytes in lymph node
is approximately 24 hr. This fact and our observation thatImmunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc. 435
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B Cell Egress from Lymph NodesFigure 2. Relocation of B Lymphocytes
within the Lymph Node Follicle after
Blockage of Lymphocyte Ingress
(A) Location of transferred B cells. Twenty million
CD45.2 B lymphocytes were transferred to recip-
ient mice (CD45.1). Two hours later, one group of
mice (n = 3) received 100 mg of CD62L antibody,
and the other group (n = 3) received PBS. Eighteen
hours after antibody injection, the lymph nodes
were harvested and immunostained for B220
and CD45.2. The CD45.2-positive cells are high-
lighted by red arrows.
(B) A relative increase in the number of transferred
B cells in the apical region after CD62L antibody
treatment. The lymph node sections were divided
into a basal region away from the lymphatics at the
T-B cell boundary and an apical region close to the
lymphatics. The number of CD45.2 B cells is
enumerated (left panel). The ratio between the
numbers of cells in the apical and basal regions
is shown (right panel).
(C) Distance from lymphatics. The distances of the
cells in the basal region from the subcapsular
sinus and the distances of the cells in the apical region from the lymphoid cortical sinusoids were measured and plotted for the PBS and CD62L antibody-treated
mice. The statistical difference is between measured distances of the transferred B cells in the apical region of the inguinal lymph node from PBS versus the
CD62L antibody-treated mice. Error bars show the mean ± standard error of the mean (SEM).B lymphocytes leave the follicle via lymphatics present along the
edge of the follicle suggest that exiting B lymphocytes may
move toward the apical face of the follicle with time. To confirm
this, we adoptively transferred B lymphocytes to recipient mice
and 2 hr later treated them with CD62L antibody. The antibody
will block further entry of lymphocytes into the lymph node
(Lepault et al., 1994). Eighteen hours later, we harvested lymph
nodes and determined the locations of transferred B lympho-
cytes by immunohistochemistry. As expected, the CD62L
antibody-treated mice had smaller follicles than did the PBS-
treated mice. In gross terms, the follicle was divided into two
regions, the basal region that is juxtaposed to the subcapsular
sinus and the apical region close to cortical lymphatics
(Figure 2A). In control lymph nodes in which there is a continuous
replenishing of their follicular lymphocytes from peripheral blood,
there were always more transferred cells in the basal region
compared to the apical region. This suggests that after entrance
into the follicle, the B cells tend to localize away from the
lymphatics and HEVs and toward the center of the lymph node
follicle. In contrast, in the antibody-treated group, a cohort of
B lymphocytes that entered during the initial 2 hr period after
transfer had moved toward the apical region (Figure 2B).
Although on average the population of cells in the CD62L anti-
body-treated mice moved from the basal region toward the
apical region, a small population of cells remained close to the
subcapsular space (Figure 2A). To better quantify the locations
of the cells relative to the lymphatic regions, we measured the
distances of the transferred cells in the apical region from the
cortical sinusoid and those in the basal region from the sub-
capsular space (Figure 2C). The most striking difference was
between the apical populations, whereas the difference between
the basal populations was not statistically significant (Figure 2C).
These results indicate that those B cells that have remained in
the lymph node the longest tend to move out of the follicle and
toward the cortical lymphatics.436 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.Location of S1PR1-Positive B Lymphocytes
in the Follicle
The level of S1PR1 expression on lymphocytes is low to nonex-
istent in peripheral blood and lymph and is upregulated within the
lymphoid tissues (Lo et al., 2005; Matloubian et al., 2004). To
study the localization of S1PR1-positive B lymphocytes in the
lymph node follicle in relation to the cortical lymphatics, we per-
formed immunohistochemistry with a S1PR1-specific antibody
(Figure 3). This antibody was raised against amino acid residues
322–381 from the human S1PR1. It crossreacts with the mouse
S1PR1 and has been used for detecting the receptor in normal
mouse tissues, but it fails to react with tissue from S1pr1/
mice (Akiyama et al., 2008). First, we verified that a control-
matched rabbit antibody showed no staining (Figure 3A). Next,
we used the S1PR1 antibody and found that most follicular
B cells exhibited a low-intensity homogenous membrane
expression (Figure 3B). We found a reduction in the membranous
S1PR1 staining on those B cells close to the cortical lymphatics
and those B cells near the subcapsular sinus as compared to the
B cells deep in the follicle (magnified images from Figure 3B and
Figure S1 available online). HEVs reacted strongly with the
S1PR1-specific antibody (Figure 3B), and the nearby LYVE-1-
positive lymphatics also reacted with the antibody, although
the intensity of staining was less than on HEVs (Figures 3C and
3D). Besides the homogenous membrane expression, we noted
occasional punctate staining. The amount of punctate staining
was higher on cells closer to the lymphatics, and most of the cells
within the lumen of the lymphatic exhibited this pattern, suggest-
ing that this may represent internalization of the receptor
(Figure 3E). To test that possibility, we examined S1PR1 expres-
sion on lymph node sections prepared from FTY720-treated or
control mice (Figures 3F and 3G). B cells with punctate and cyto-
plasmic S1PR1 staining were much more numerous in the
section from the FTY720-treated mice. In contrast to our findings
in the B cells, we did not see punctate staining on the lymphatic
Immunity
B Cell Egress from Lymph NodesFigure 3. Location of S1PR1-Positive B Lymphocytes within
the Lymph Node Follicle
(A and B) B220, CD3, and S1PR1 immunostaining. Thin lymph node sections
were immunostained as indicated. Rabbit IgG is the control antibody (A) for
S1PR1 immunostaining. Magnified images of the white boxed regions in (B)
are shown in the lower panels, the left two from deep in the follicle and the right
two from the T-B cell border.
(C) B220 and LYVE-1 immunostaining. Thin lymph node sections were immu-
nostained as indicated.
(D) S1PR1 and LYVE-1 immunostaining around HEV and lymphatic. The left
panel shows S1PR1 immunostaining in the region outlined by the white box
from (C). Arrows indicate lymphatic region. The right panel shows S1PR1
and LYVE-1 staining of the same region.
(E) S1PR1 immunostaining of cells in the lymphatics. The region outlined by the
white box in (D) contains cells within lymphatic lumen. The upper panel shows
LYVE-1 (green) versus S1PR1 (red), and the lower panel shows LYVE-1 (green)
versus B220 (white).
(F and G) S1PR1 immunostaining of lymph node sections from FTY720-treated
and control mice. Mice were treated with FTY720 (1 mg/kg body weight for
18 hr or not). Lymph node sections (7 mm) were stained with antibodies against
B220 (white), LYVE-1 (green), and S1PR1 (red). White box areas are magnified,
and S1PR1 staining is shown. Lymphatic endothelium staining is indicated by
arrows.and vascular endothelium, although we did note a slight
enhancement in the staining of the lymphatic endothelium from
the FTY720-treated mice. These results indicate that S1PR1
signaling occurs in B cells located in the region of the cortical
lymphatics and that FTY720 treatment results in a prolonged
downregulation of receptor expression.
Long-Term FTY720 Treatment Decreases B Cell Motility
and the Frequency of Interaction with the Lymphatic
Endothelium
To determine whether the LYVE-1 antibody could be used for
delineating the lymphatics near to lymph node follicles in vivo,
we transferred fluorescently labeled splenic B cells into syngenic
mice, followed 12 hr later by injection of LYVE-1 conjugated to
Alexa Fluor-594 subcutaneously in the region that drains the
inguinal lymph node. Twenty-four hours after B cell transfer,
we used intravital TP-LSM to image the inguinal lymph node.
We collected a 250 mm image stack (individual slices every
3 mm). The LYVE-1 antibody nicely stained lymphatic structures
near to the lymph node follicle, similar to what we had observed
with fixed samples (similar experiments with an isotype-matched
labeled antibody did not reveal these structures; data not
shown). Transferred B cells were noted in the lumen (Figure 4A
and Movie S1), indicating that the antibody had not blocked
egress. Although LYVE-1-deficient mice have normal lymphatic
development and function (Gale et al., 2007), some adverse
effect of the antibody on lymphocytes crossing the lymphatic
endothelium remains possible. In contrast to the cortical
lymphatics, many macrophages can be observed within the
subcapsular sinus and medullary lymphatics (Ohtani and Ohtani,
2008). To verify that we were imaging cortical and not medullary
lymphatics, we performed TP-LSM of the inguinal lymph node of
a mouse previously injected with a fluorescently labeled macro-
phage marker, CD169 (sialoadhesion), and with the LYVE-1
antibody. As expected, the cortical lymphatics were largely
devoid of CD169-positive cells (Figure S2). Because we wanted
to image those B lymphocytes ready to exit the lymph node
follicle rather than recent immigrants, we blocked further
lymphocyte ingress into lymph nodes by treating the mice with
CD62L antibody 18 hr prior to imaging. To verify that we had
identified lymphatic structures relevant to B lymphocyte egress,
we compared mice treated with FTY720 and untreated mice
24 hr prior to imaging. The LYVE-1 antibody was administered
12 hrs prior to staining. Images showing LYVE-1 staining and
transferred B cells from either nontreated or FTY720-treated
mice are shown (Figures 4B and 4C). For purposes of trafficking
individual B cells, we divided the lymph node into three regions
designated c, b, and a (right panels, Movies S2 and S3). In
non-FTY720-treated mice, the majority of the B lymphocytes
resided in the lymph node follicle; some B lymphocytes resided
near lymphatic region. The cells in the basal region (c) of the
lymph node had a slightly higher velocity than did those in the
apical region (b) and those near the lymphatics (a) (Figure 4D).
The B cells in all regions were significantly affected by FTY720
treatment, with an approximately 40% reduction in their
expected velocities (Figure 4E). Treatment with FTY720 moder-
ately increased the density of B cells within the lymph node
follicle, presumably because of the reduction in B lymphocyte
egress (Figure 4F). Tracking only those individual B cellsImmunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc. 437
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B Cell Egress from Lymph NodesFigure 4. TP-LSM Intravital Imaging of LYVE-1-Stained Structures Near the Lymph Node Follicle in the Presence or Absence of FTY720
(A) 27 mm z projection of intravital two-photon image stack of inguinal lymph node stained with Alexa Fluor-594-conjugated LYVE-1 antibody for visualizing
a cortical lymphatic sinusoid (from Movie S1). Ten million CMFDA-stained B cells (green) were transferred to the recipient mouse, and Alexa Fluor-594-conju-
gated LYVE-1 antibody (20 mg) was injected subcutaneously adjacent to the inguinal lymph node. Lymphatic structures visualized by LYVE-1 antibody are red.
(B and C) A typical TP-LSM slice from an imaging stack of control and FTY720-treated mice shows LYVE-1-positive signal (red), transferred B cells (green), and
second harmonics (cyan) (image from Movies S2 and S3). The scale bar represents 200 mm. Right panels show global tracking of adoptively transferred B cells in
intact inguinal lymph nodes. Yellow tracks have an average track speed above the mean of the total, and cyan tracks have an average track speed below the
mean. Indicated boxes were analyzed below.
(D and E) Average velocity of adoptively transferred B cells in selected areas (white boxes). The boxes are over the following sites in control and FTY720-treated
mice, respectively: a, the LYVE-1 positive region; b, follicle adjacent to the LYVE-1-positive region; c, middle of the follicle.
(F) Density of adoptively transferred B cells in B cell follicles. Average number of cells was calculated in four different selected areas in B cell follicles from control
and FTY720-treated mice.
(G) Average velocity of selected tracks (control: n = 7; FTY720-treated: n = 11), which were coordinated with the starting time point in the adjacent area to the
LYVE-1-positive region (green and blue box in [B] and [C], respectively.)
(H) The mean displacement of selected tracks from (H) is plotted versus the square root of time. Mean motility coefficient between 0.5 min1/2 and 3.16 min1/2 is
20.57 ± 2.25 um2/min for controls and 2.976 ± 0.2753 um2/min for FTY720-treated mice. Data are representative of one of three experiments performed.
(I) Frequency at which B cells in the neighborhood of the cortical sinusoids approach the endothelium. B cells within 30 mm of the cortical lymphatic endothelium
were manually tracked for determining whether they engaged the endothelium for a minimum of 2 min over a 30 min imaging span. Data are from representative
regions in four separate imaging experiments. 220 cells from FTY720-treated mice and 145 cells from nontreated cells were tracked. The percentages of cells that
engaged the epithelium are shown.attempting to cross the lymphatic endothelium showed that
FTY720 treatment reduced their velocity and decreased their
displacement as a function of the square root of time of tracking
as compared to cells from nontreated mice (Figures 4G and 4H).
Examination of the cells within 30 microns of a cortical lymphatic
and enumeration of the percentage, which engaged the endo-
thelium for more than 2 min, revealed that FTY720 treatment
reduced the frequency by more than 2-fold (Figure 4I). Thus,
FTY720 treatment reduced the motility of B cells in the lymph438 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.node and modestly reduced the frequency at which the cells
engaged the lymphatic endothelium.
FTY720 Treatment Markedly Decreases the Frequency
at which B Cells Cross the Lymphatic Endothelium
Zoomed images of individual B cells near cortical lymphatics
from a control and a FTY720-treated mouse are shown (Figures
5A and 5B). Similar to what we had observed with immunohisto-
chemistry, no transferred B cells were observed in the lumen of
Immunity
B Cell Egress from Lymph Nodesthe lymphatics near the lymph node follicles after FTY720 treat-
ment (Figure 5B). Imaging nontreated mice revealed that some
cells approached and rapidly crossed the lymphatic endothe-
lium, requiring approximately 2–3 min, whereas other cells
meandered around the lymphatic sinusoid for several minutes
prior to crossing or leaving the vicinity (Figure 5C, Movie S4).
On rare occasions, a cell crossed in the opposite direction
(data not shown). Those cells that successfully crossed the
endothelium appeared to do so by migrating through openings
or channels in a step-wise process similar to what has been
described by light-microscopy examinations of rat lymphocytes
crossing the lymphatic endothelium of lacteals (Azzali, 1990).
The crossing cell first engaged the endothelium, then extended
a filopodial-like membrane projection into the site of passage,
and finally squeezed through the channel-like opening, reaching
the lumen of the lymphatic vessel. Often the cell rounded up after
Figure 5. B Lymphocyte Migration from the B Cell Follicle
into Adjacent Lymphatic Sinusoids Is Blocked by FTY720
(A and B) Single-slice images (from Movie S4 and S5) with the
indicated area selected were further analyzed below. The scale
bar represents 50 mm. The protocol was similar to that used as
in Figure 4. Selected white boxes were zoomed.
(C and D) Image sequences from the white box (from Movies S4
and S5). Delineated lymphatic endothelium is marked with
a dotted white line. The yellow circles surround three penetrating
cells in (C) and two cells unable to penetrate the barrier in (D). The
time indicator shows the time of the snapshot image from 30 min
movies. The dragon tail traces the previous six time points. The
images are representative of one of three experiments performed.
(E) Individual transferred B cells that engaged a cortical lymphatic
for a minimum of 2 min were observed during a 30 min imaging
period. The durations that 25 cells remained associated with the
lymphatic endothelium were recorded from intravital TP-LSM
imaging experiments performed with either untreated or
FTY720-treated mice. The durations during which cells engaged
the endothelium but failed to cross are indicated in red, whereas
the durations during which cells engaged and passed are indi-
cated in green. If a cell disengaged from the endothelium and
then re-engaged, that duration is indicated in blue. Cells that
remained bound to the endothelium for the duration of the imaging
are indicated with an asterisk.
entering into the lymphatic (Figure S3). In contrast, we
failed to observe a single B lymphocyte cross into the
cortical sinusoids in the FTY720-treated mice
(Figure 5D and Movie S5). Some B cells hovered close
to the endothelium without engaging it. Those B cells
that approached the endothelium failed to penetrate
it. Individual cells occasionally persisted in their
attempts to cross into the sinusoid lumen; however,
we failed to observe any cell attempting to squeeze
through the endothelium as we had observed in the
absence of drug. Analyzing 25 B cells in the absence
of FTY720 that engaged the lymphatic endothelium
for a minimum of two minutes revealed that 15 cells
crossed the endothelium, 2 cells remained engaged
for the duration of the imaging period without crossing,
and 8 cells engaged but failed to cross. Some of the
cells that crossed did so but required several attempts
before passing. In contrast, among 25 cells that
engaged the endothelium in FTY720-treated mice, none of the
cells crossed (Figure 5E). These data indicate that FTY720
does not prevent B cells from engaging the lymphatic endothe-
lium, but it does block the ability of the cells to cross from the
lymph node parenchyma into the lymph.
Short-Term FTY720 Treatment Blocks the Entrance
of B Lymphocytes into Lymphatics and Increases
Engagement with the Cortical Lymphatics,
but Does Not Affect Their Motility
To examine the short-term effects of FTY720 on B lymphocyte
motility and egress, we performed intravital microscopy either
prior to or 4 hr after FTY720 administration. In these experiments,
we transferred labeled B cells, 12 hr later injected the LYVE-1
antibody, and after 12 more hours prepared the mouse for
imaging. After 30 min of imaging, we injected FTY720 and waited
Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc. 439
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B Cell Egress from Lymph Nodes4 hr before imaging the same mouse inguinal lymph node prep-
aration. A previous time course experiment had shown that
B cells stopped crossing the LYVE-1-positive endothelium
approximately 2 hrs after administration of the drug (C.P. and
J.H.K., unpublished data). Shown is the same lymph node follicle
before and after FTY720 (Figure S4). In contrast to what we had
observed after a 24 hr exposure to FTY720, the motility of B cells
in the different regions of the lymph node follicle and close to
the lymphatics remained unaffected by FTY720 treatment
(Figure S4). Tracking individual B cells attempting to cross the
lymphatic endothelium revealed no change in their average
speed, but we did observe some greater variability in the
displacement after FTY720 treatment. In contrast to the long-
term FTY720 treatment, in which we saw a reduction in the
number of cells approaching the cortical lymphatics, the short
term FTY720 treatment increased the number of cells that
engaged the endothelium by approximately 50%. Because we
imaged the same inguinal lymph node preparation before and
after 4 hr after FTY720 treatment, we could observe the behavior
of cells around the same cortical lymphatics. Examination of indi-
vidual B cells that bound the endothelium for a minimum of 2 min
revealed that 11/25 cells crossed prior to FTY720, whereas none
of the cells after 4 hr of FTY720 crossed. Again after FTY720
treatment, several cells tried to cross repeatedly without
success (Figure S4 and Movies S6 and S7). These data indicate
that a shorter duration of FTY720 treatment also blocks B cells
from crossing the lymphatic endothelium, but that in contrast
to the more prolonged treatment, the B cell motility is unaffected.
S1PR3, Not S1PR1,Mediates B Lymphocyte Chemotaxis
to S1P, yet S1pr3/ B Cells Transit through Lymph
Nodes Normally
Our imaging experiments suggested, as previously reported with
T cells, that FTY720 blocks B cells from crossing the lymphatic
endothelium. Yet FTY720 treatment does not recapitulate a
physiologic process, and the argument that S1PR1 functions
as a chemoattractant receptor facilitating the movement of
B and T cells from the lymph node parenchyma into the efferent
lymphatics remained persuasive. Therefore, we used several
different approaches to test the importance of S1P-mediated
chemotaxis in B lymphocyte egress. First, we examined the
role of S1PR1 in mediating B cell chemotaxis to S1P in vitro.
To do so, we examined the response of follicular B cells in stan-
dard chemotaxis assays with S1P as a chemoattractant in
conjunction with a S1PR1 antagonist (VPC23019). Although at
higher concentrations, VPC23019 also has antagonistic activity
at S1PR3, we used a concentration that is relatively specific for
S1PR1 (Davis et al., 2005). Surprisingly, we found that antagonist
did not diminish the S1P-mediated chemotaxis response, but
rather enhanced it, indicating that another S1P receptor medi-
ates S1P-directed B cell chemotaxis (Figure 6A). A previous
study had shown that S1pr3/ B cells responded poorly to
S1P in standard chemotaxis assays (Girkontaite et al., 2004).
We verified those results. S1pr3/ B cells had no detectable
chemotaxis to S1P. This defect is most pronounced with
marginal zone B cells, which respond better to S1P than do other
B cell subsets, but follicular B cells also fail to respond (Fig-
ure 6B). We then examined whether the loss of S1PR3 affected
B cell transit through lymph nodes or the motility of B cells within440 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.the inguinal lymph node follicle or adjacent to the lymphatics. We
found that the S1pr3/ B cells behaved nearly identically to
normal B cells in their entrance into lymph nodes, their transit
time through lymph nodes, and their motility both in the follicle
and near lymphatics as assessed by adoptive transfer and
TP-LSM imaging experiments (Figures 6C–6E). Together, these
data argue that S1P-triggered chemotaxis does not substantially
contribute to B lymphocyte egress from lymph nodes.
Gnai2/ B Cells, which Respond Poorly to S1P
and Chemokines, Transit through Lymph Nodes
More Efficiently Than Do Wild-Type B Cells
When compared to wild-type B cells, Gnai2/ B cells home
poorly to lymph nodes, respond less well in chemotaxis assays
to CXCL12 and CXCL13, enter lymph node follicles poorly, and
once in the follicle have a reduced interstitial velocity (Han
et al., 2005). As might be predicted, they also exhibit a sharp
reduction in S1P-mediated chemotaxis in vitro (Figure 7A). Yet,
their poor chemotactic response to chemokines and S1P does
not impair their transit through lymph nodes (Figure 7B). After
18 hr of CD62L antibody treatment, 60% and 74% of the trans-
ferred wild-type B cells versus 74% and 92% of the transferred
Gnai2/ B cells had exited the inguinal and popliteal lymph
nodes, respectively. Over the time frame examined, approxi-
mately 30% more of the Gnai2/ B cells had exited than had
wild-type B cells. To facilitate the imaging of Gnai2/ B cells,
we adoptively transferred twice as many of these cells as we
did wild-type cells. Intravital TP-LSM and tracking studies
revealed that the Gnai2/ B cells moved slower, with less
displacement, and less straight than did the wild-type cells
both in the middle of the follicle and near the LYVE-1-defined
cortical lymphatics (Figure 7C). Nearly twice as many wild-type
cells localized to the center of the follicle as did the Gnai2/
B cells, whereas the ratio was nearly reversed near the
lymphatics (Figure S5). The location of Gnai2/ B cells versus
wild-type B cells along with cell tracks over a 30 min imaging
period are shown (Figure 7D). During 1.5 hr of imaging, we
observed more Gnai2/ B cells crossing into the lymphatics
adjacent to the lymph node follicle than we did wild-type B cells
(Figure 7E). Measuring the distances from the edge of LYVE-
1-defined lymphatics in surrounding 2003 2003 20 mm3 spaces
of 100 control and 100 Gnai2/ B cells also demonstrated the
more proximal localization of Gnai2/ B cells compared to
control cells. Very similar results were found with pertussis
toxin-treated B cells as compared to nontreated B cells
(Figure S6). These results suggest that the reduction in B cell
responsiveness to signals that locate the B cells within the lymph
node follicle results in a failure of the B cells to move away from
the lymph node egress sites, thereby enhancing the frequency of
lymph node egress.
DISCUSSION
The above findings aid our understanding of B cell trafficking
through lymph nodes, provide insights into the role of S1P
in the regulation of B cell egress from lymph nodes, and delineate
the major effect of FTY720 on B cell retention in lymph nodes.
The ready access of B cells to cortical lymphatic sinusoids
provides an elegant solution for their egress from lymph nodes.
Immunity
B Cell Egress from Lymph NodesFigure 6. B Lymphocyte Lymph Node Egress Does Not Depend upon S1P-Mediated Chemotaxis
(A) Blocking S1PR1 does not inhibit S1P-triggered chemotaxis. A chemotaxis assay was performed with follicular B cells (FB; B220+, CD21 moderate, CD23+)
with increasing concentrations of S1P in the presence or absence of VPC23019 (0.5 mM). Data are representative of one of four experiments performed and are
presented as specific migration.
(B) S1PR3 mediates marginal zone and follicular B cell chemotaxis to S1P. Specific migration of follicular and marginal zone (MZB; B220+, CD21 high, CD23-)
B cells from wild-type and S1pr3/ mice to S1P (0.05 mM) and CCL19 (100 ng/ml) is shown. Data are representative of one of three experiments preformed.
(C) Homing assay. Equal numbers of labeled wild-type and S1pr3/ B cells were intravenously transferred to recipient mice (two experiments each with three
pairs of mice). Two hours after transfer, cells from blood, spleen, inguinal lymph nodes, and popliteal lymph nodes of recipient mice were analyzed with a flow
cytometer. Shown are the actual number of transferred B cells found in blood, spleen, and lymph nodes.
(D) Lymph node transit assay. Ten million labeled wild-type cells and the same number of labeledS1pr3/B cells were intravenously transferred to recipient mice
(two experiments each with six pairs of mice). CD62L antibody (100 mg/mouse) was injected intravenously 2 hr after cell transfer to four pairs of mice. Two
matched pairs of mice were injected with PBS, and the numbers of recovered cells were measured. 12 hr (two pairs) and 24 hr (two pairs) after antibody injection,
the cells were recovered from the indicated sites. The ratios between the cells recovered 12 hr after antibody or 24 hr after antibody, and prior to antibody treat-
ment are shown in the right panels.
(E) Motility parameters. Adoptively transferred labeled wild-type and S1pr3/ B cells were imaged by TP-LSM intravitally and tracked over 30 min in either the
middle of the lymph node follicle or in the region of LYVE-1-positive lymphatics of the inguinal lymph node. Average velocity, displacement, and relative straight-
ness of the tracks are plotted for individual cells. Data are representative of one of three experiments performed. Error bars show mean ± SEM.The relocalization of B cells that have resided in the lymph node
longer toward the cortical lymphatics is consistent with their
being a major site of egress. Some B cells in the follicle tended
to reside close to the subcapsular sinus, and we noted an occa-
sional transferred B cell in the sinus; however, we never
observed a B cell crossing from the follicle into the sinus. The
degree of S1PR1 expression correlated with the known sources
of S1P within the lymph node. B cells within the lymphatics had
a punctate staining pattern, likely evidence of receptor internal-
ization (Watterson et al., 2002). Intravital TP-LSM allowed the
imaging of cells around the cortical lymphatic sinusoids and
the visualization of cells as they squeezed through the lymphatic
endothelium. Treatment with FTY720 blocked the entrance of
B cells into the cortical lymphatic sinusoids. Finally, the in vitrostudies of S1P chemotaxis and the in vivo experiments with
S1pr3/ and Gnai2/ B cells argue that S1P-mediated chemo-
taxis is of minor importance for B lymphocyte egress.
As detailed in the Introduction, several previous studies had
provided evidence for the existence of cortical sinusoids that
could provide egress sites for B lymphocytes (Anderson and
Anderson, 1975; Kurokawa and Ogata, 1980; Soderstrom and
Stenstrom, 1969; He, 1985). Yet, their importance has not
been fully appreciated because B cells are commonly thought
to exit in the lymph node via the medullary sinus. In the course
of our studies, a published report identified LYVE-1-positive
lymphatic sinusoids in the neighborhood of lymph node folli-
cles; however, the focus of that study was the role of CCR7
and S1PR1 in T cell egress (Pham et al., 2008). In this study,Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc. 441
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B Cell Egress from Lymph NodesFigure 7. Gnai2/ B Cells Exhibit Reduced S1P and Chemokine Triggered Migration but Rapidly Transit Lymph Nodes
(A) Migration assay. A chemotaxis assay of S1P and CXCL12 was performed with wild-type andGnai2/B cells (one representative experiment of four is shown).
(B) Lymph node transit assay. Twelve million labeled wild-type cells and the same number of labeled Gnai2/ B cells were intravenously transferred to recipient
mice (two experiments each with four pairs of mice). Two pairs of mice were injected with CD62L antibody (100 mg/mouse) intravenously 2 hr after cell transfer,
and the number of cells recovered was enumerated 18 hr after antibody injection. Two pairs of mice were injected with PBS 2 hr after transfer, and the cells recov-
ered from indicated sites were determined immediately. The ratios between the cells recovered after 18 hr antibody treatment and prior to antibody treatment are
shown in the last panel.
(C) Motility parameters. Adoptively transferred labeled wild-type (10 million) and Gnai2/ B cells (20 million) were imaged intravitally by TP-LSM in the inguinal
lymph node. The cells were tracked over 30 min in either the middle of the lymph node follicle or in the region of LYVE-1-positive lymphatics. Average velocity,
displacement, and relative straightness of the tracks are plotted for individual cells.
(D) Tracks of wild-type andGnai2/ B cells around cortical lymphatics. The left panel shows an image from intravital TP-LSM of wild-type and Gnai2/ B cells in
the region of lymphatics of the inguinal lymph node. The right panel shows the same image with superimposed tracks from wild-type (blue) and Gnai2/ (green)
B cells from 30 min of imaging.
(E) Cells observed crossing cortical lymphatics. The number of wild-type and Gnai2/ B cells observed entering cortical lymphatics is shown. Data were
combined from three separate 30 min imaging experiments.
(F) Localization of cells relative to LYVE-1 positive cortical lymphatics. Imaging spaces of 250 mm 3 250 mm 3 20 mm (x, y, z) were centered around a LYVE-
1-positive region, and the distances of 100 wild-type and 100 Gnai2/ B cells from the lymphatic sinusoid were measured at arbitrary time points. Data are
from three separate imaging experiments. Error bars show mean ± SEM.we used thick sections of the inguinal lymph nodes stained for
B220 and LYVE-1, which gave a greater appreciation of the
extent of the cortical sinusoids. The cortical sinusoids near the
lymph node follicles were predominately filled with B cells,
whereas T cells filled the deep cortical lymphatic sinusoids.
As expected, treating mice with FTY720 emptied the cortical
sinusoids of B cells, providing further evidence that these struc-
tures provide a major site of egress. Although we have focused
on the role of cortical lymphatics in mediating B cell egress for
those lymph node follicles located close to the medulla, the
medullary sinus may also serve as egress sites for them.
The precise mechanism by which S1PR1 regulates lympho-
cyte egress from lymphoid organs has been surprisingly difficult
to delineate (Cahalan and Parker, 2008). Much of the controversy
has revolved around reconciling data from the analysis of mice
reconstituted with fetal liver from S1pr1/ mice and mice442 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.treated with FTY720. One model argued for the importance of
lymphocyte-expressed S1PR1. Compelling data supports
a role for the S1PR1 as a chemoattractant receptor (Cyster,
2005). The presence of S1P lyases in the tissues creates a S1P
gradient between the lymph node parenchyma and the lymph.
Disruption of that gradient impairs lymphocyte egress (Schwab
et al., 2005). Like other chemoattractant receptors, the S1PR1
couples to Gi (Okamoto et al., 1998). Furthermore, B and
T cells express significant levels of S1PR1; a S1P gradient
in vitro causes T and B cells to migrate, although only a small
percentage of them do so, and the migration is sensitive to
pertussis toxin (Allende et al., 2004; Lo et al., 2005; Matloubian
et al., 2004). However, other data complicate this picture. The
administration of S1PR1 antagonists to mice has not recapitu-
lated the phenotype observed with FTY720 (Sanna et al.,
2006). Lymphocytes express several S1P receptors in addition
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B Cell Egress from Lymph Nodesto S1PR1. S1PR3, not S1PR1, mediates marginal zone B cell
chemotaxis, yet S1PR1 functions to localize cells in the marginal
zone, not S1PR3 (Cinamon et al., 2004; Girkontaite et al., 2004).
We have shown that follicular B cells also use S1PR3, not
S1PR1, to trigger S1P-mediated chemotaxis. S1pr3/ B cells
did not respond in a S1P chemotaxis assay, and a S1PR1 antag-
onist did not inhibit normal B cell chemotaxis. Yet S1pr3/
B cells transited through lymph nodes relatively normally.
Although these data argue that the S1PR1 does not mediate
B lymphocyte chemotaxis, S1PR1 could function in vivo via a
mechanism not modeled by current in vitro chemotaxis assays.
That S1PR1, and presumably S1PR3, on lymph node B cells
have been engaged is supported by the immunohistochemistry
data, which demonstrated evidence of S1PR1 downregulation
and internalization around and within the cortical lymphatic
sinusoids. The enrichment of exiting B cells around the cortical
lymphatics and the altered frequencies at which B cells
approached the lymphatic endothelium after FTY720 treatment
suggests that one consequence of S1P signaling is to retain
B cells near the cortical lymphatics. Because S1PR1 agonism
inhibits the entry of tissue T cells into afferent lymphatics by
arresting T cells at the basal surface of lymphatic vessels (Ledg-
erwood et al., 2008), one possibility is that S1PR1 signaling
enhances B cell adhesion to the lymphatic endothelium. Our
imaging data provide some support of this possibility. Short-
term FTY720 treatment, which has an agonistic effect on B cell
S1P receptors, caused an increase in cells contacting the
lymphatic endothelium, whereas 24 hr of FTY720 treatment,
which reduced S1P receptor expression, decreased B cell
contacts. However, arguing against this possibility is the fact
that no essential role for a4 and b2 integrins has been found for
T cell lymph node egress (Lo et al., 2005). Another possibility is
that S1PR1 signaling could directly interfere with intranodal
retention signals and thereby bias the cells toward egress. It
has been reported that S1P can interfere with responses to che-
mokines (Graeler et al., 2002), and it is known that signaling
through one G protein-coupled receptor can decrease signaling
through another (Reiter and Lefkowitz, 2006; Kehrl, 2006).
Finally, a third possibility is that S1PR3 promotes the localization
of B cells close to cortical lymphatics. However, in their absence,
no substantive impact on lymph node trafficking occurs.
The other major model argues that S1PR1 on endothelial cells
regulates lymphocyte egress (Rosen et al., 2003). In this model,
endothelial S1PR1 agonism shuts the lymphatic endothelial
portals. Imaging studies have provided major support for this
model (Sanna et al., 2006; Wei et al., 2005). Two previous studies
imaged T cells intravitally with fluorescently labeled wheat germ
agglutinin to identify the lymphatic vessels; however, in only one
of those studies were cells visualized crossing the medullary
lymphatic endothelium (Nombela-Arrieta et al., 2007; Sanna
et al., 2006). The most comprehensive study of T cells crossing
into the medullary sinus was performed with explanted lymph
nodes, a design that offers many advantages but disrupts the
normal blood supply and flow of lymph (Wei et al., 2005). In
that study, T cells moved slower in the medullary region than in
the cortex, a result verified by intravital microscopy (Nombela-
Arrieta et al., 2007; Sanna et al., 2006). Furthermore, the expo-
sure of explanted lymph nodes to the S1PR1 agonist
SEW2871 reduced the interstitial velocity of medullary T cellswithout affecting the cortical T cells (Wei et al., 2005). The
SEW2871-mediated slowing could be reversed with a competi-
tive S1PR1 antagonist. In contrast, we did not observe any short-
term effect of FTY720 exposure on average B cell motility. We
also imaged inguinal lymph node after treatment of mice with
SEW2871 without observing any effect on B cell motility (C.P.,
unpublished data). One possible explanation for this difference
is that inhibiting lymphocyte egress with S1PR1 agonists causes
more ‘‘log jamming’’ in the medullary region than it does around
the cortical lymphatics. There may also be differences between
B and T lymphocytes in their S1P response profiles. Imaging
T lymphocytes in the T cell zone of explanted lymph nodes after
FTY720 exposure revealed no change in their velocity (Huang
et al., 2007), whereas follicular B cells slowed after a similar
duration of drug treatment. Imaging the SEW2871-treated lymph
nodes also revealed an inability of T lymphocytes to enter the
medullary sinus that was reversible by adding a S1PR1 antago-
nist (Wei et al., 2005). Similarly, 2 hr after FTY720 administration,
we did observe B cells entering into the cortical lymphatic
sinusoids. Some B lymphocytes pushed repeatedly against the
lymphatic endothelium without breaching it, a result consistent
with the possibility that the lymphatic endothelium portals are
closed. Alternatively, an S1PR1 signal delivered to B cells is
needed for them to negotiate their way through the endothelium.
Overall, our data underscore the importance of cortical
lymphatic sinusoids for B lymphocyte egress. The major effect
of FTY720 treatment is to prevent B cells from crossing the endo-
thelium, but not from engaging it. No requirement for S1P-trig-
gered chemotaxis in B lymphocyte egress from the lymph
node was found. Our study and others lead us to the following
model of B lymphocyte lymph node transit. B cells enter the
lymph node cortical ridge through HEVs and within 1–2 hr enter
into the follicle, moving toward the follicle center and reacquiring
their S1P receptors. In the absence of antigen activation, over
the next 12–18 hr the cells gradually lose responsiveness to
CXCL13, which frees them to move back toward the follicle
edge and cortical lymphatics. Several different mechanisms
may account for a reduction in CXCL13 responsiveness. The
journey to the lymph node follicle center can be short circuited
by inhibiting chemokine receptor signaling. This allows cells to
remain near the cortical lymphatics, thereby enhancing their
probability of egress. Although the S1pr3/ B cells exited lymph
nodes similarly to wild-type cells, a reasonable role for the
S1PR3 would be to help localize cells toward the cortical
lymphatics. Once in the neighborhood of the cortical lymphatics,
B cells will periodically encounter the lymphatic endothelium.
Here, a lymphocyte S1PR1 signal is needed to facilitate the cell’s
passage through the lymphatic endothelium. Why S1PR3, which
can mediate S1P chemotaxis, cannot provide this signal remains
enigmatic. The ability to image B and T cells crossing the cortical
lymphatic sinusoids to enter into the efferent lymph should
provide a valuable tool for future studies of lymphocyte traf-
ficking through lymph nodes and across endothelial surfaces.
EXPERIMENTAL PROCEDURES
Mice
Wild-type C57BL/6J (CD45.2) and congenic strain B6.SJL (CD45.1) mice of
ages between 8 and 14 weeks were purchased from Taconic and The JacksonImmunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc. 443
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(National Institute of Environmental Health Sciences, National Institutes of
Health [NIH]). The S1pr3/ mice were kindly provided by R.L. Proia (National
Institute of Diabetes and Digestive and Kidney Diseases, NIH). The mice were
housed under specific pathogen-free conditions and used in accordance with
the guidelines from the Institutional Animal Care Committee at the NIH.
Reagents
The following antibodies to mouse antigens were used: B220-Alexa Fluor-488,
CD3-Alexa Fluor-647, CD8-biotin, CD4-biotin, CD11c-biotin, Gr-1-biotin,
CD45.2-biotin, CD62L (BD Biosciences), CD169 (AbD Serotec), LYVE-1
(R&D Systems), S1PR1 (Cat # sc-25489, Santa Cruz), CD21-FITC, CD23-
PE-Cy7, IgD-PE, and IgM-APC (eBiosciences). Anti-goat IgG-Alexa Fluor-
633 (Invitrogen), anti-goat IgG-Rhodamine Red-X, anti-rabbit IgG-Rhodamine
Red-X, streptavidin-Rhodamine Red-X, and normal donkey serum (Jackson
ImmunoResearch) were also used. Dynabeads M-280 streptavidin was
purchased from Invitrogen. FTY720 was kindly provided by V. Brinkmann
(Novartis Pharmaceutical). D-erythro-sphingosine 1-phosphate and VPC23019
were purchased from Avanti Polar Lipids. RPMI 1640 medium supplemented
with 2 mM L-glutamine and 25 mM HEPES, charcoal-dextran filtered fetal
bovine serum, penicillin/streptomycin solution (10,000 IU/ml each), and
100 mM sodium pyruvate were purchased from Hyclone. Murine CCL19 and
CXCL12 were purchased from R&D Systems. Fatty-acid-free bovine serum
albumin (FAF-BSA) was purchased from Sigma-Aldrich.
Adoptive B Lymphocyte Transfer for Immunohistochemistry
The donor (CD45.2) splenic B lymphocytes were isolated by negative deple-
tion with biotinylated antibodies to CD4, CD8, CD11c, and GR-1 and Dyna-
beads M-280 streptavidin. The cell purity was approximately 95%. Twenty
million B lymphocytes were injected into the tail vein of recipients (CD45.1).
Two hours later, one group of mice (n = 3) received 100 mg of CD62L antibody
in the tail vein, and the other group (n = 3) received PBS to serve as a control.
After 17–18 hr of antibody injection, all mice were sacrificed, and lymph
nodes and spleens were harvested for immunohistochemistry and flow
cytometry.
FTY720 Treatment
For the immunocytochemistry, mice were gavaged with either 1 mg/kg body
weight FTY720 or PBS as a control (n = 3 mice/group). After 18 hr, mice
were killed and lymph nodes and spleen were harvested. A few lymph nodes
were fixed in 4% paraformaldehyde for thick-section confocal imaging. Other
lymph nodes and spleen were used in flow cytometry for enumerating the
number of B lymphocytes in the FTY720-treated group versus the untreated
group. For details on the intravital microscopy experiments, see below.
Immunostaining
For making 100 mm thick lymph node sections, freshly isolated nodes were
fixed in a 4% paraformaldehyde solution in PBS overnight at 4C. Fixed lymph
nodes were individually placed in a 24-well plate, and melted (37C–38C)
1.5% agarose in PBS was poured over them. Solidified blocks of agarose-
containing lymph node were glued on a tissue holder in a Leica VT1000 S
Vibratome, and 100 mm slices were cut in a bath of ice-cold PBS. The sections
were stained with the indicated antibodies. In brief, sections were each placed
in an individual well of a 24-well plate in 0.2% Triton X-100 in PBS at room
temperature. After incubation for 2–3 hr, the detergent solution was drained
and sections were submerged in 10% blocking serum for 2–3 hr at room
temp. The sections were then put in 10% blocking serum containing primary
antibodies (1–2 mg) overnight at 4C. The next day, sections were washed
for at least 2 hr at room temperature with several changes of PBS. The sections
were then treated with fluorescent-tagged secondary antibodies and washed
as was done with primary antibodies. The tissue sections were slowly rocked
during all the incubations. Finally, the sections were put on a glass slide and
mounted in antifade medium (Invitrogen). Microscopy was performed with
a Leica TCS SP5 confocal microscope, and images were processed in Adobe
Photoshop CS and Imaris v.6.0.1 (Bitplane). In some experiments, freshly
isolated lymph nodes were snap frozen in Tissue-Tek OCT compound (Sakura
Finetek). 6–7 mm frozen sections were stained with a standard technique.
Images were acquired with a Leica TCS SP5 confocal microscope.444 Immunity 30, 434–446, March 20, 2009 ª2009 Elsevier Inc.Intravital Two-Photon Microscopy and Analysis
Inguinal lymph nodes were prepared for intravital microscopy with a slight
modification of a previously described method (Han et al., 2005). Splenic B cells
prepared from C57BL/6 mice were labeled for 15 min at 37C with 5mM CMFDA
or 50 mM CMF2HC. Ten million labeled cells in 200 ml of PBS were adoptively
transferred by tail vein injection into 6- to 10-week-old recipient mice. For
long-term exposure to FTY720, mice were injected with FTY720 (1.5 mg/kg
body weight) or vehicle by intraperitoneal injection 24 hr after cell transfer.
Six hours later, recipient mice were injected intravenously with CD62L antibody
(100 mg per mouse) for blocking further lymphocyte ingress into the lymph
node. Twelve hours prior to imaging, mice were injected subcutaneously with
20 mg of LYVE-1 antibody conjugated with Alexa Fluor-594 (Monoclonal anti-
body labeling kit, Invitrogen) in 200 ml PBS close to the inguinal lymph node.
After anaesthetizing the mice by intraperitoneal injection 300 mg/kg of Avertin
(tribromoethanol, Sigma), the skin and fatty tissue over inguinal lymph node
were removed. For visualizing both the B cell follicle and the lymphatic area
in the same imaging field, the exposed inguinal lymph node was gently rotated
90 from its original orientation. The mouse was placed in a prewarmed cover-
glass chamber slide (Nalgene, Nunc). The chamber slide was then placed into
a temperature-controlled chamber mounted on the microscope (The Cube and
Box, Life Imaging Services). The temperature of the air was monitored and
maintained at 37.0C ± 0.5C. Inguinal lymph node was intravitally imaged
from the capsule over a range of depths (60–250 mm). For the short-term expo-
sure to FTY720 experiments, recipient mice were prepared in a manner similar
to the above procedure. The recipient mice were injected with FTY720 after
a 30 min initial imaging. Four hours later, the same field was imaged again.
The CD62L antibody was not used in the short-term experiments. Two-photon
imaging was performed with a Leica TCS SP5 inverted five-channel confocal
microscope (Leica Microsystems) equipped with a 203multi-immersion objec-
tive, 0.7 NA (immersion medium used was 80% glycerol). Two-photon excita-
tion was provided by a Mai Tai Ti:Sapphire laser (Spectra Physics) with a 10 W
pump, tuned to 810 or 830 nm. For four-dimensional analysis of cell migration,
stacks of four or ten sections (z step = 3 mm) were acquired every 15 or 30 s for
providing an imaging volume of 9 or 27 mm in depth. Emitted fluorescence was
collected with a four-channel nondescanned detector. Wavelength separa-
tions were as follows: a dichroic mirror at 495 nm followed by a dichroic mirror
at 455 nm and then a 405/20 nm emission filter for second harmonics and a 480/
40 nm emission filter for CMF2HC, and a dichroic mirror at 565 nm followed by
a 525/50 nm emission filter for CMFDA and a 620/60 nm emission filter for Alexa
Fluor-594. Sequences of image stacks were transformed into volume-rendered
four-dimensional movieswith ImarisX64 version 6.1 software, and spot analysis
was used for semiautomated tracking of cell motility in three dimensions with
the following parameters: autoregressive motion algorithm, estimated diameter
10 mm, background subtraction true, maximum distance 20 mm, and maximum
gap size 3. The data set was corrected for tissue drift, and calculations of the cell
velocity and displacement were performed. All statistical analysis was per-
formed with GraphPad Prism (GraphPad Software). Significance of statistics
was calculated with unpaired t test for two nonparametric data and with Krus-
kal-Wallis test for three nonparametric data. Annotation and final movie compli-
cation was performed with Adobe Premiere Pro CS3 version 3.0.1 (Adobe).
Chemotaxis
Chemotaxis assays were performed with a transwell chamber (Costar) as
previously described (Han et al., 2005). Cells were added in a volume of
100 ml to the upper wells of a 24-well Transwell plate with a 5 mm insert. Lower
wells contained 600 ml of assay medium with various concentrations of chemo-
kines and lipids. The number of cells that migrated to the lower well after a 2 hr
incubation at 37C was counted with a flow cytometer. The percent migration
was determined by first taking the difference between the number of transmi-
grating cells of a given subset in the presence of chemoattractant and those for
which no chemoattractant was present. The fraction of migrated cells obtained
for each condition was divided by the total number of cells of that subset in the
starting cell suspension. The results were multiplied by 100, and graphs of the
data were generated (Prism, Graphpad Software).
Homing and Lymph Node Transit Assays
B cells from control and experimental mice were labeled with 1 mM CMFDA or
2.5 mM CMTMR for 15 min at 37C, and 7 to 20 million cells of each population
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nodes, and popliteal lymph nodes were removed and gently dissociated into
single-cell suspensions. Peripheral blood was collected by retro-orbital eye
bleeding. After removal of red blood cells with Tris-NH4Cl, the cells were
resuspended in PBS containing 1% BSA at 4C. Flow-cytometric analysis
was performed on a BD FACS Calibur flow cytometer, and the data were
analyzed with FlowJo software (Tree Star). Forward- and side-scatter parame-
ters were used for gating on live cells. The lymph node transit assay used
a similar initial approach, but 2 hrs after the cell transfer, the control and exper-
imental mice were injected intravenously with CD62L antibody (100 mg/mouse)
for each time point. After the indicated duration, the spleen, lymph nodes, and
peripheral blood were collected, and cell numbers were determined as in the
homing assay. The ratios between the numbers of cells in the various compart-
ments 2 hrs after transfer versusafter CD62Lantibody injection were calculated.
SUPPLEMENTAL DATA
Supplemental Data include six figures and nine movies and can be found with this
articleonlineathttp://www.immunity.com/supplemental/S1074-7613(09)00077-6.
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